|
|
26.06.25 - 12:33
|
Nature′s Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock (GlobeNewswire EN)
|
|
LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions....
|
|
25.06.25 - 22:03
|
Nature′s Sunshine Products, Inc. Announces Launch of Secondary Public Offering of Common Stock (GlobeNewswire EN)
|
|
LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”)....
|
|
16.06.25 - 15:30
|
Teva, Shanghai Fosun Partner To Develop TEV-56278 (AFX)
|
|
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278 ut......
|
|
|
06.06.25 - 11:15
|
FOSUN PHARMA Repurchases 800K A-Shrs, Involving ~RMB20M (AAStocks)
|
|
FOSUN PHARMA (02196.HK)(600196.SH) announced that it repurchased a total of 800,300 shares of the company on the Shanghai Stock Exchange today (6th), with the price per share ranging from RMB24.92 to RMB25.14, involving a total of approximately RMB19.9988 million. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
12.05.25 - 07:15
|
Research: Citi Lists H-shrs w/ US Exports (Table) (AAStocks)
|
|
Stock│Forecast for Percentage of Revenue from Export to US in 2025COWELL (01415.HK)│30%ASMPT(00522.HK)│15%BYD ELECTRONIC (00285.HK)│around 25-30%.KLN (00636.HK)│15-20%AAC TECH (02018.HK)│12%FOSUN PHARMA (02196.HK)│11%SUNNY OPTICAL (02382.HK)│9%Q TECH (01478.HK)│<1%CHERVON ......
|
|
|
|
26.03.25 - 03:30
|
Fosun Pharma Announces 2024 Annual Results (PR Newswire)
|
|
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global......
|
|
|
|
|
|
|
30.10.24 - 03:43
|
Fosun Pharma Announces 2024Q3 Financial Results (PR Newswire)
|
|
Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the......
|
|
28.08.24 - 12:12
|
Fosun Pharma Announces 2024 Interim Results (PR Newswire)
|
|
Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK),......
|
|
|
25.07.24 - 00:08
|
XFRA : DIVIDEND/INTEREST INFORMATION - 26.07.2024 - CNE100001M79 (XETRA)
|
|
Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird cum Dividende/Zinsen gehandelt am 25.07.2024 und ex Dividende/Zinsen am 26.07.2024
The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its pre-dividend/interest day on 25.07.2024 and its ex-dividend/interest day on 26.07.2024...
|
|